Takahashi, Naoto
Kanda, Mitsuro
Yoshikawa, Takaki
Takiguchi, Nobuhiro
Fujitani, Kazumasa
Miyamoto, Katsufumi
Ito, Yuichi
Takayama, Osamu
Imano, Motohiro
Mitsumori, Norio
Sakamoto, Junichi
Morita, Satoshi
Kodera, Yasuhiro
Article History
Received: 20 January 2018
Accepted: 7 March 2018
First Online: 13 March 2018
Compliance with ethical standards
: All procedures followed were in accordance with the ethical standards of the responsible institutional committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.
: Dr. Yoshikawa reports grants from Japanese Foundation for Multidisciplinary Treatment of Cancer during the conduct of the study; grants and personal fees from Chugai Pharmaceutical, Taiho Pharmaceutical, and Novartis Pharmaceuticals Japan; personal fees from Abbott Japan, Ono Pharmaceutical, Eli Lilly Japan, Kaken Pharmaceutical, Yakult Honsha, Nippon Kayaku, Johnson and Johnsons, Covidien Japan, Takeda Pharmaceutical, and Olympus outside the submitted work. Dr. Sakamoto received a consulting fee from Takeda Pharmaceutical and personal fees from Tsumura and Chugai Pharmaceutical Co. Ltd outside the submitted work. Dr. Morita received personal fees from Daiichi-Sankyo and Chugai Pharmaceutical outside the submitted work. Dr. Kodera reports grants and personal fees from Taiho Pharmaceutical, Chugai Phamaceutical, Sanofi, Merck Serono, Yakult Honsha, Daiichi Sankyo, Otsuka Pharmaceutical Factory, Takeda Pharmaceutical, Kaken Pharmaceutical, Ono Pharmaceutical, Johnson & Johnson, and Eli Lilly Japan; and grants from Pfizer Japan, EA Pharma, Covidien Japan, Shionogi, Bristol Myers Squib, Japan Blood Products Organization, AbbVie GK, Eizai, Abbott Japan, CSL Behring, Tsumura, Nippon Kayaku, Novartis Pharmaceuticals Japan, KCI, Toyama Chemical, and Maruho; and personal fees from MSD, Olympus, and Asahi Kasei Pharma outside the submitted work.